IDX184

IDX184 is a liver-targeted, orally bioavailable nucleotide prodrug developed for the treatment of hepatitis C virus (HCV) infection. It is designed to deliver 2′-methylguanosine monophosphate (2′-MeG-MP) directly to hepatocytes, bypassing the rate-limiting phosphorylation step required by earlier nucleoside analogs. Once inside liver cells, IDX184 is efficiently converted into its active triphosphate form (2′-MeG-TP), which acts as a potent and specific inhibitor of the HCV NS5B RNA-dependent RNA polymerase, thereby blocking viral replication[1][2][4]. IDX184 demonstrated significant antiviral activity in early clinical trials but did not progress beyond Phase IIb for HCV. Research has continued on its potential use against other emerging viral diseases such as Zika virus and coronaviruses including MERS and SARS-CoV-2[4].

Other names

2′-methylguanosine monophosphate prodrugidx184idx-184idx 184